FI943635A0 - Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten vasta-aineiden suunnittelu, kloonaus ja ekspressio - Google Patents

Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten vasta-aineiden suunnittelu, kloonaus ja ekspressio

Info

Publication number
FI943635A0
FI943635A0 FI943635A FI943635A FI943635A0 FI 943635 A0 FI943635 A0 FI 943635A0 FI 943635 A FI943635 A FI 943635A FI 943635 A FI943635 A FI 943635A FI 943635 A0 FI943635 A0 FI 943635A0
Authority
FI
Finland
Prior art keywords
cloning
planning
expression
monoclonal antibodies
human interleukin
Prior art date
Application number
FI943635A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI943635L (fi
FI943635A7 (fi
Inventor
Chuan-Chu Chou
Nicholas J Murgolo
John S Abrams
Chung-Her Jenh
Mary E Petro
Jon E Silver
Stephen Tindall
William T Windsor
Paul J Zavodny
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of FI943635A0 publication Critical patent/FI943635A0/fi
Publication of FI943635L publication Critical patent/FI943635L/fi
Publication of FI943635A7 publication Critical patent/FI943635A7/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FI943635A 1992-02-06 1993-02-04 Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten v asta-aineiden suunnittelu, kloonaus ja ekspressio FI943635A7 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83284292A 1992-02-06 1992-02-06
PCT/US1993/000759 WO1993016184A1 (en) 1992-02-06 1993-02-04 Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5

Publications (3)

Publication Number Publication Date
FI943635A0 true FI943635A0 (fi) 1994-08-05
FI943635L FI943635L (fi) 1994-08-05
FI943635A7 FI943635A7 (fi) 1994-08-05

Family

ID=25262763

Family Applications (1)

Application Number Title Priority Date Filing Date
FI943635A FI943635A7 (fi) 1992-02-06 1993-02-04 Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten v asta-aineiden suunnittelu, kloonaus ja ekspressio

Country Status (21)

Country Link
US (1) US6451982B1 (cg-RX-API-DMAC10.html)
EP (1) EP0625201A1 (cg-RX-API-DMAC10.html)
JP (2) JPH07505767A (cg-RX-API-DMAC10.html)
KR (2) KR0150060B1 (cg-RX-API-DMAC10.html)
CN (1) CN1077991A (cg-RX-API-DMAC10.html)
AR (1) AR248044A1 (cg-RX-API-DMAC10.html)
AU (1) AU683836B2 (cg-RX-API-DMAC10.html)
CA (1) CA2129445A1 (cg-RX-API-DMAC10.html)
CZ (1) CZ291039B6 (cg-RX-API-DMAC10.html)
FI (1) FI943635A7 (cg-RX-API-DMAC10.html)
HU (1) HUT67943A (cg-RX-API-DMAC10.html)
IL (1) IL104620A (cg-RX-API-DMAC10.html)
NO (1) NO942912L (cg-RX-API-DMAC10.html)
NZ (1) NZ249633A (cg-RX-API-DMAC10.html)
PL (1) PL176393B1 (cg-RX-API-DMAC10.html)
RU (1) RU94045919A (cg-RX-API-DMAC10.html)
SG (1) SG49597A1 (cg-RX-API-DMAC10.html)
SK (1) SK280610B6 (cg-RX-API-DMAC10.html)
TN (1) TNSN93012A1 (cg-RX-API-DMAC10.html)
WO (1) WO1993016184A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA93779B (cg-RX-API-DMAC10.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
USRE39548E1 (en) * 1994-06-17 2007-04-03 Celltech R&D Limited Interleukin-5 specific recombinant antibodies
US6056957A (en) * 1994-08-04 2000-05-02 Schering Corporation Humanized monoclonal antibodies against human interleukin-5
US7399837B2 (en) 1995-12-22 2008-07-15 Smithkline Beecham Corporation Recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
US5683892A (en) * 1994-12-23 1997-11-04 Smithkline Beecham Corporation DNA encoding recombinant IL-5 antagonists useful in treatment of IL-5 mediated disorders
EP0800536B1 (en) * 1994-12-23 2006-11-29 Smithkline Beecham Corporation Recombinant il-5 antagonists useful in treatment of il-5 mediated disorders
US5683983A (en) * 1995-06-07 1997-11-04 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
US5677280A (en) * 1995-06-07 1997-10-14 Glaxo Group Limited Peptides and compounds that bind to the IL-5 receptor
US5668110A (en) * 1995-06-07 1997-09-16 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
CA2205007C (en) 1995-09-11 2010-12-14 Masamichi Koike Antibody against human interleukin-5 receptor .alpha. chain
US6228360B1 (en) * 1998-08-19 2001-05-08 Ajinomoto Co., Inc. Antithrombotic agent and humanized anti-von Willebrand factor monoclonal antibody
US7109299B1 (en) 1999-12-16 2006-09-19 Affymax, Inc. Peptides and compounds that bind to the IL-5 receptor
KR100453877B1 (ko) 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
ES2327830T3 (es) 2002-03-29 2009-11-04 Schering Corporation Anticuerpos monoclonales humanos anti-interleuquina-5 y metodos y composiciones que los contienen.
US7927840B2 (en) * 2006-09-11 2011-04-19 Gen Probe Incorporated Method for detecting West Nile Virus nucleic acids in the 3′ non-coding region
EP3241915B1 (en) * 2002-10-16 2021-06-23 Gen-Probe Incorporated Compositions and methods for detecting west nile virus
BRPI0317376B8 (pt) 2002-12-17 2021-05-25 Merck Patent Gmbh proteína de fusão de anticorpo-il2 designada como hu14.18-il2, usos da mesma, vetor e composição farmacêutica
ITRM20030601A1 (it) * 2003-12-24 2005-06-25 Lay Line Genomics Spa Metodo per l'umanizzazione di anticorpi e anticorpi umanizzati con esso ottenuti.
JP4954709B2 (ja) 2004-10-28 2012-06-20 協和発酵キリン株式会社 子宮内膜症治療剤
EP3072522B1 (en) 2005-01-06 2019-04-24 Novo Nordisk A/S Anti-kir combination treatments and methods
WO2006099875A1 (en) 2005-03-23 2006-09-28 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
ITRM20050290A1 (it) 2005-06-07 2006-12-08 Lay Line Genomics Spa Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP2606906A1 (en) 2007-04-30 2013-06-26 GlaxoSmithKline LLC Methods for administering anti-IL-5 antibodies
CA2719786A1 (en) 2008-03-28 2009-10-01 Glaxosmithkline Llc Methods of treatment
AU2009306708A1 (en) * 2008-10-23 2010-04-29 F. Hoffmann-La Roche Ag Determination of immunoglobulin encoding nucleid acid
PT2654790T (pt) 2010-12-22 2019-05-16 Teva Pharmaceuticals Australia Pty Ltd Anticorpo modificado com semivida melhorada
EP2791172B1 (en) 2011-12-16 2017-07-19 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
US9677018B2 (en) 2013-01-09 2017-06-13 Thyssenkrupp Industrial Solutions Ag Process for the production of synthesis gas from hard coal
HUE050202T2 (hu) 2014-09-08 2020-11-30 Cephalon Inc Reslizumab alkalmazása közepestõl súlyosig terjedõ eozinofil asztma kezelésére
KR20240099511A (ko) 2015-08-24 2024-06-28 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 생물제약 조성물
EP3634467A4 (en) 2017-06-06 2021-07-28 GlaxoSmithKline LLC BIOPHARMACEUTICAL COMPOSITIONS AND METHODS FOR PEDIATRIC PATIENTS
JP2019026625A (ja) * 2017-08-03 2019-02-21 日本全薬工業株式会社 抗イヌｃｄ２０モノクローナル抗体
US11224653B2 (en) 2017-08-24 2022-01-18 Cephalon, Inc. Treatment strategy for non-responders to 100MG subcutaneous mepolizumab
MX2020003034A (es) * 2017-09-29 2020-07-22 Jiangsu Hengrui Medicine Co Anticuerpo il-5, fragmento de union a antigeno del mismo y su aplicacion medica.
CN109942706A (zh) * 2017-12-21 2019-06-28 三生国健药业（上海）股份有限公司 结合人il-5的单克隆抗体、其制备方法和用途
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5096704A (en) 1988-11-03 1992-03-17 Schering Corporation Method of treating eosinophilia
ZA898322B (en) * 1988-11-03 1990-11-28 Schering Corp Method of preventing or reducing eosinophilia
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2041271A1 (en) * 1990-04-30 1991-10-31 Bradford A. Jameson Peptide analogs to proteins of the immunoglobin superfamily
IL104620A (en) 1992-02-06 2000-02-29 Schering Plough Corp Humanized monoclonal antibodies against human interleukin-5

Also Published As

Publication number Publication date
EP0625201A1 (en) 1994-11-23
SK91894A3 (en) 1995-02-08
IL104620A0 (en) 1993-06-10
KR950700413A (ko) 1995-01-16
SG49597A1 (en) 1998-06-15
FI943635L (fi) 1994-08-05
NO942912D0 (cg-RX-API-DMAC10.html) 1994-08-05
CZ291039B6 (cs) 2002-12-11
IL104620A (en) 2000-02-29
CZ191094A3 (en) 1994-12-15
RU94045919A (ru) 1996-11-10
AU683836B2 (en) 1997-11-27
FI943635A7 (fi) 1994-08-05
CA2129445A1 (en) 1993-08-07
NZ249633A (en) 1995-12-21
AR248044A1 (es) 1995-05-31
JP2000210097A (ja) 2000-08-02
HUT67943A (en) 1995-05-29
HU9402293D0 (en) 1994-10-28
PL176393B1 (pl) 1999-05-31
WO1993016184A1 (en) 1993-08-19
KR0150060B1 (ko) 1998-08-17
NO942912L (no) 1994-10-06
CN1077991A (zh) 1993-11-03
JPH07505767A (ja) 1995-06-29
AU3656093A (en) 1993-09-03
ZA93779B (en) 1993-08-05
US6451982B1 (en) 2002-09-17
TNSN93012A1 (fr) 1994-03-17
SK280610B6 (sk) 2000-05-16

Similar Documents

Publication Publication Date Title
FI943635A0 (fi) Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten vasta-aineiden suunnittelu, kloonaus ja ekspressio
FI962377A0 (fi) Humanisoituja vasta-aineita ja niiden käyttö
FI941572A7 (fi) Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
DK666389A (da) Monoklonalt antistof
DE69324596D1 (de) Rekombinante humanisierte anti-cytomegalovirus antikörper
AU2782789A (en) Monoclonal antibodies against human interleukin-4 and hybridomas producing the same
FR2631239B1 (fr) Anticorps monoclonal humain et hybridome le produisant
FI940811L (fi) Ihmisen monoklonaalisia anti-Rhesus(D) -vasta-aineita ja niitä tuottavat solulinjat
NO177311C (no) Anti-fucosylceramid monoklonalt antistoff
NO170691C (no) Onkofoetale spesifikke monoklonale antistoffer og anvendelse derav
DK69690D0 (da) Humane anti-rh(d) monoklonale antistoffer
FI945485L (fi) Monoklonaaliset vasta-aineet ja niiden käyttö
DK717888D0 (da) Monoklonale antistoffer
FI952171L (fi) Hepatiitti B-pinta-antigeeneille aktiivisten ihmisen monoklonaalisten vasta-aineiden tuotto
FI943524A7 (fi) Hepatiitti C -viruksen vastaisia monoklonaalisia vasta-aineita ja anti -idiotyyppisiä vasta-aineita
DK370089A (da) Anti-urokinase monoklonale antistoffer
FI895829A7 (fi) Ihmisen monoklonaaliset vasta-aineet rabiesvirusta vastaan
FI944314L (fi) Vasta-aineen immunogeenisyyden selektiivinen muuttaminen
DK413389A (da) Monoklonale antistoffer
HK1008833A (en) Design, cloning and expression of humanized monoclonal antibodies against human interleukin-5
DK240286D0 (da) Monoklonale antistoffer
FI935038A7 (fi) Kasvaimiin liittyvä monoklonaalinen vasta-aine 81AV78
NO922878D0 (no) Noeytralisering og/eller adcc-formidlende monoklonalt hiv-antistoff
GB9210930D0 (en) Monoclonal antibodies and their use